Log in

Relevant bibliographies by topics / Adjuvant chemoradiation

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Adjuvant chemoradiation'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adjuvant chemoradiation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Adjuvant chemoradiation"

1

van Kol, Kim, Renée Ebisch, Jurgen Piek, Maaike Beugeling, Tineke Vergeldt, and Ruud Bekkers. "Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate." Cancers 13, no. 24 (2021): 6190. http://dx.doi.org/10.3390/cancers13246190.

Full text

Abstract:

Objective: To determine the incidence of pathology-proven residual disease in adjuvant hysterectomy specimens in patients with cervical cancer, treated with chemoradiation therapy. Secondly, to assess a possible association for pathology-proven residual disease regarding the time between chemoradiation therapy and adjuvant hysterectomy. Additionally, the survival rate and complication rate were assessed. Methods: PubMed, EMBASE, and the Cochrane database were searched from inception up to 8 March 2021. Results: Of the 4601 screened articles, eleven studies were included. A total of 1205 patien

APA, Harvard, Vancouver, ISO, and other styles

2

Markelis, Rytis, Žilvinas Endzinas, Mindaugas Kiudelis, et al. "Adjuvant therapy after curative resection with D2 lymphadenectomy for gastric cancer: Results of a prospective clinical trial." Medicina 45, no. 6 (2009): 460. http://dx.doi.org/10.3390/medicina45060060.

Full text

Abstract:

Objective. Adjuvant chemoradiation for gastric cancer is used more frequently, but there is no general opinion about the effect of this treatment. The aim of this study was to compare adjuvant chemoradiation with adjuvant chemotherapy after radical operation for stomach cancer. Material and methods. A total of 133 patients were included in this prospective study. Sixty-three patients after curative gastrectomy and D2 lymphadenectomy for gastric cancer were assigned to the chemoradiotherapy group and 70 to the chemotherapy group. The groups were identical by age, sex, and cancer stages. Toxicit

APA, Harvard, Vancouver, ISO, and other styles

3

Mayer. "Efficacy of Neo- and Adjuvant Treatment Modalities in Gastrointestinal Cancer Patients." Swiss Surgery 7, no. 6 (2001): 239–42. http://dx.doi.org/10.1024/1023-9332.7.6.239.

Full text

Abstract:

Data which have emerged from randomized clinical trials are inconclusive regarding the efficacy of neoadjuvant chemoradiation therapy for patients with esophageal cancer. In 2001, available data appear to support the use of adjuvant chemoradiation therapy following the complete resection of a gastric cancer, adjuvant chemotherapy following the resection of a stage III (and - probably - "high-risk" stage II) colon cancer, and the use of adjuvant (and most likely neoadjuvant) chemoradiation therapy for stages II and III rectal cancer.

APA, Harvard, Vancouver, ISO, and other styles

4

Chen, Yongshun, Daxuan Hao, Xiaoyuan Wu, et al. "Neoadjuvant or adjuvant chemoradiation therapy for stage II-III esophageal squamous cell carcinoma." Journal of Clinical Oncology 33, no. 3_suppl (2015): 202. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.202.

Full text

Abstract:

202 Background: Esophageal cancer is the eighth most common cancer worldwide, and especially in China is the fourth most common cause of death. Clinical trials have explored the value of neoadjuvant or adjuvant chemoradiation in potentially resectable esophageal squamous cell carcinoma (ESCC); however, these studies have produced conflicting results. This retrospective study was performed to investigate whether patients with resectable stage II/III ESCC should receive neoadjuvant or adjuvant therapy in addition to surgery. Methods: A review of stage II/III ESCC patients who underwent esophagec

APA, Harvard, Vancouver, ISO, and other styles

5

Seaton, Max, Andrew Hanna, Cherif Boutros, and Nader Hanna. "Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database." Therapeutic Advances in Medical Oncology 11 (January 2019): 175883591984243. http://dx.doi.org/10.1177/1758835919842438.

Full text

Abstract:

Background: The optimal multimodality therapy for pancreatic ductal adenocarcinoma in the body or tail of the pancreas (PDAC-BT) is unclear. The purpose of this study was to compare overall 5-year survival between patients treated with adjuvant chemotherapy, adjuvant chemoradiation, and surgery alone. Methods: Patients from the National Cancer Database (1998–2012) with resected stage I or II PDAC-BT were included. Overall survival between the three treatment groups was compared using Cox proportional-hazards regression, propensity-score matching, and the Kaplan–Meier method. Results: Of the 70

APA, Harvard, Vancouver, ISO, and other styles

6

Ahmed, Aabra, Ryan W. Walters, Timothy Dean Malouff, Mridula Krishnan, Javaneh Jabbari, and Peter T. Silberstein. "Adjuvant therapy in stage II pancreatic cancer: A National Cancer Database analysis." Journal of Clinical Oncology 35, no. 4_suppl (2017): 283. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.283.

Full text

Abstract:

283 Background: Oldfield et al (2015) showed the conflicting evidence regarding the effect of adjuvant chemotherapy vs. chemoradiation in pancreatic cancer. Using patients identified by the National Cancer Database (NCDB), we are the largest study to compare survival in stage II pancreatic cancer patients who received adjuvant chemotherapy, chemoradiation, radiation, or no adjuvant therapy. Methods: We identified 65,091 patients with stage II pancreatic cancer who received surgery only or surgery in combination with chemotherapy, radiation, or chemoradiation. Between-therapy survival differenc

APA, Harvard, Vancouver, ISO, and other styles

7

Alkış, Hilal, Rukiye Arıkan, Aleksei Kornienko, Hatice Kübra Gündüz, and Mustafa Adlı. "Timing of adjuvant chemoradiation for pancreatic cancer with positive surgical margins." Journal of Translational and Practical Medicine 2, no. 2 (2023): 60–63. http://dx.doi.org/10.51271/jtpm-0042.

Full text

Abstract:

Aims: Impact of adjuvant chemoradiation timing on the outcome of pancreatic cancer patients with positive surgical margins is unknown. The aim of this study was to evaluate the effect of adjuvant chemoradiation timing for margin positive pancreatic cancer patients. Methods: A total of 36 pancreatic adenocarcinoma patients with positive surgical margins and received adjuvant chemoradiation were included in the study. The median radiation dose was 50.4 Gy in 28 fractions. The primary study variable was the timing of chemoradiation, grouped as immediate (after ? 1 cycle of chemotherapy) and delay

APA, Harvard, Vancouver, ISO, and other styles

8

Ali, Nasir, Azmina Tajdin Valimohammad, Ahmed Nadeem Abbasi, Muhammad Atif Mansha, Asim Hafiz, and Bilal Mazhar Qureshi. "Chemoradiation and the Role of Adjuvant Chemotherapy in Lymph Nodal–Metastatic Cervical Cancer." Journal of Global Oncology, no. 4 (December 2018): 1–4. http://dx.doi.org/10.1200/jgo.2017.009852.

Full text

Abstract:

Purpose To report the long-term outcome in lymph nodal–metastatic cervical squamous cell cancer after chemoradiation followed by adjuvant chemotherapy. Patients and Methods Between 2010 and 2013, five patients were diagnosed with advanced cervical cancer with clinically involved para-aortic lymph nodes (ie, International Federation of Gynecology and Obstetrics stage IVB). These patients were treated with concurrent chemoradiation therapy followed by adjuvant chemotherapy. Concurrent chemoradiation consisted of cisplatin given once per week concomitantly with extended-field radiation therapy fo

APA, Harvard, Vancouver, ISO, and other styles

9

Phillips, John G., Theodore S. Hong, and David P. Ryan. "Multidisciplinary Management of Early-Stage Rectal Cancer." Journal of the National Comprehensive Cancer Network 10, no. 12 (2012): 1577–85. http://dx.doi.org/10.6004/jnccn.2012.0160.

Full text

Abstract:

Because patients with locally advanced rectal cancer are at high risk for both recurrence and distant disease, they require adjuvant therapy. In the United States, the current standard of care is neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Neoadjuvant chemoradiation has been shown to improve local recurrence rates and decrease toxicity. However in the era of total mesorectal excision surgery, no study has shown a survival benefit to either chemoradiation or postoperative chemotherapy. Newer biologic therapies, although promising in initial early trials, have yet t

APA, Harvard, Vancouver, ISO, and other styles

10

Lv, Jiahua, Tao Li, Qifeng Wang, et al. "Neoadjuvant versus adjuvant chemoradiotherapy for stage II–III esophageal squamous cell carcinoma: A propensity score-matched analysis." Journal of Clinical Oncology 37, no. 15_suppl (2019): e15524-e15524. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e15524.

Full text

Abstract:

e15524 Background: Many clinical trials have explored the value of neoadjuvant or adjuvant chemoradiation therapy in stage II–III squamous cell carcinoma (ESCC). However, these studies have produced conflicting results. This retrospective study was performed to investigate whether patients with stage II/III ESCC should receive neoadjuvant or adjuvant therapy in addition to surgery. Methods: A total of 206 patients with clinical stage II and III ESCC who underwent esophagectomy and either neoadjuvant or adjuvant chemoradiation were included. On the basis of the sequence of surgery and chemoradi

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Adjuvant chemoradiation"

1

Wells, Thomas Peter Edward. "Optimising the therapeutic ratio of adjuvant breast cancer treatments : assessment of chemoradiation heart damage with serum cardiac troponin I and the use of open MRI in adjuvant breast radiotherapy planning." Thesis, University of Bristol, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.424051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bibault, Jean-Emmanuel. "Prédiction par Deep Learning de la réponse complète après radiochimiothérapie pré-opératoire du cancer du rectum localement avancé Labeling for big data in radiation oncology: the radiation oncology structures ontology Big data and machine learning in radiation oncology: state of the art and future prospects Deep learning and radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer." Thesis, Sorbonne Paris Cité, 2018. https://wo.app.u-paris.fr/cgi-bin/WebObjects/TheseWeb.woa/wa/show?t=2388&f=17288.

Full text

Abstract:

L’utilisation de systèmes informatiques pour formaliser, organiser et planifier le traitement des patients a abouti à la création et à l’accumulation de quantité importante de données. Ces informations comprennent des caractéristiques démographiques, socio-économiques, cliniques, biologiques, d’imagerie, et, de plus en plus, génomiques. La médecine et sa pratique, fondées sur la sémiologie et la physiopathologie, vont être profondément transformées par ce phénomène. La complexité et la quantité des informations à intégrer pour prendre une décision médicale pourrait dépasser rapidement les capa

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Adjuvant chemoradiation"

1

J, John Madhu, ed. Chemoradiation: An integrated approach to cancer treatment. Lea & Febiger, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Choy, Hak. Chemoradiation in Cancer Therapy. Humana Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Choy, Hak. Chemoradiation in Cancer Therapy. Humana Press, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Adjuvant chemoradiation"

1

Pandya, Naimish, Michael C. Garofalo, and William F. Regine. "Adjuvant Chemoradiation Therapy for Pancreatic Cancer." In Pancreatic Cancer. Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-77498-5_44.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kaiser, Adeel, William F. Regine, Naimish Pandya, and Michael C. Garofalo. "Adjuvant Chemoradiation Therapy for Pancreatic Cancer." In Pancreatic Cancer. Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7193-0_44.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kaiser, Adeel, William F. Regine, Naimish Pandya, and Michael C. Garofalo. "Adjuvant Chemoradiation Therapy for Pancreatic Cancer." In Pancreatic Cancer. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6631-8_44-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Glimelius, Bengt, and Peter Nygren. "Will Adjuvant Chemotherapy Improve Outcome After Preoperative Chemoradiation?" In Multidisciplinary Management of Rectal Cancer. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-25005-7_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Garofalo, Michael C., and William F. Regine. "Adjuvant Chemoradiation for Pancreatic Cancer: Past, Present and Future." In Pancreatic Cancer. Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-69252-4_31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mehta, Sushma, and Moni Abraham Kuriakose. "Principles of Surgical Management of Oral Cancer." In Oral and Maxillofacial Surgery for the Clinician. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-1346-6_82.

Full text

Abstract:

AbstractOral Cavity Squamous Cell Carcinoma (OSCC), is a heterogenous disease with respect to risk factors, geographic predelictions, treatment response and outcome. Although non-surgical treatment is employed in other head and neck sub-sites, surgery is the primary treatment modality to treat oral cancers followed by adjuvant treatment either in the form of radiation or chemoradiation based on the risk features on final histopathology. It is utmost importance that all the patients before undergo treatment are discussed and treatment plan is formulated in a multidisciplinary tumor board. This

APA, Harvard, Vancouver, ISO, and other styles

7

Bishr, Mai K., and Ben O’Leary. "Mechanism of Action and Potential Use of SMAC Mimetics in Head and Neck Squamous Cell Carcinoma (HNSCC)." In Critical Issues in Head and Neck Oncology. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-84539-0_6.

Full text

Abstract:

Abstract Patients with head and neck squamous cell carcinoma (HNSCC) often present with locally advanced disease and despite aggressive treatment, relapse remains a significant challenge. Evasion of apoptosis, a mode of regulated cell death, has been implicated in treatment resistance and poor prognosis, partly via overexpression of inhibitor of apoptosis proteins (IAPs). Thus, therapeutic strategies targeting the anti-apoptotic machinery are being explored; one such strategy is the design of compounds that mimic the naturally occurring endogenous second mitochondria-derived activator of caspa

APA, Harvard, Vancouver, ISO, and other styles

8

Szturz, Petr, and Jan B. Vermorken. "High-Dose Three-Weekly or Low-Dose Weekly Cisplatin during Radiation, What to Prefer?" In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_10.

Full text

Abstract:

AbstractIn locally advanced squamous cell carcinoma of the head and neck, adding three cycles of high-dose (100 mg/m2) cisplatin every three weeks to definitive or adjuvant radiotherapy can significantly improve locoregional control and survival. One of the major drawbacks is severe acute toxicity with about 40% of patients developing mucositis, up to one fourth suffering from dysphagia, and at least 20% having bone marrow suppression. Late toxicity has been under- and sometimes mis-reported and may even be responsible for an increase in non-cancer-related deaths in long-term survivors. Moreov

APA, Harvard, Vancouver, ISO, and other styles

9

Madhavan Nair, Lekha, Rejnish Ravi Kumar, Malu Rafi, Farida Nazeer, Kainickal Cessal Thommachan, and Kunnambath Ramadas. "Chemotherapy in Nasopharyngeal Carcinoma." In Pharynx - Diagnosis and Treatment. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98550.

Full text

Abstract:

Nasopharyngeal carcinoma is a unique disease entity among head and neck cancers due to its epidemiology and clinical behavior. Non-keratinizing or undifferentiated carcinoma is the most common histological type in endemic areas. Radiotherapy is the treatment for early-stage disease. With the widespread use of IMRT, loco-regional control has improved significantly in locally advanced diseases. But distant metastasis continues to be the most common pattern of failure. To address this issue, chemotherapy has been incorporated into radiotherapy in various settings; as concurrent, induction, and ad

APA, Harvard, Vancouver, ISO, and other styles

10

Depboylu, Bengü. "The Impact of Genetic Mutational Typing of Endometrial Carcinoma for Adjuvant Oncologic Treatment and Treatment Outcome." In Current Researches in Health Sciences-III. Özgür Yayınları, 2023. http://dx.doi.org/10.58830/ozgur.pub305.c1251.

Full text

Abstract:

The adjuvant treatment of endometrial carcinomas took a different turn when ESGO/ESTRO/ESP announced its prognostic risk group guide in 2020. The Cancer Genome Atlas (TCGA) Research Network Classification and the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) algorithm were integrated into clinical practice. Therefore, by combining genomic traits with molecular subtypes, doctors have enhanced patient care and risk stratification for endometrial cancer. Surgery (hysterectomy and bilateral salphingooopherectomy with or without lymph node dissection) is the primary treatment

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Adjuvant chemoradiation"

1

Ma, Daniel J., Katharine A. Price, Eric J. Moore, et al. "Abstract CT227: MC1273: Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiation in HPV associated oropharynx cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-ct227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wild, Aaron T., Ariel E. Marciscano, Manuel Hidalgo, et al. "Abstract A87: Preliminary results of a phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-a87.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

He, M., Z. Lin, H. Wang, Q. Zhou, and D. Zou. "EPV068/#398 Randomized controlled trial of the efficacy of adjuvant chemotherapy in patients with residual lesions after concurrent chemoradiation therapy for locally advanced cervical cancer (CQGOG0102)." In IGCS 2021 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-igcs.136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Singh, S., V. Goel, V. Talwar, et al. "Neo-adjuvant chemotherapy followed by surgery versus definitive chemo radiation as treatment for localized carcinoma cervix." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685273.

Full text

Abstract:

Background: Cervical cancer is ranked as the most common cancer in Indian women, second most common cancer worldwide and the leading cause of death in the developing countries. In the developing countries majority of the patients are diagnosed at locally advanced stages. The standard treatment of locally advanced cervical cancer is concomitant chemoradiation (CTRT) using platinum based chemotherapy. However, some randomized studies have shown improved results for patients receiving neoadjuvant chemotherapy (NACT) followed by surgical resection in comparison to patient receiving radiation alone

APA, Harvard, Vancouver, ISO, and other styles

5

Lawrence, Yaacov Richard, Jennifer Moughan, Anthony Magliocco, et al. "Abstract 3553: Elevated expression of mismatch repair enzyme MLH1 is associated with prolonged overall survival in resected pancreatic cancer treated with adjuvant chemoradiation, a biomarker analysis of RTOG 9704." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!